Evidence map›Paper›PMID 33033592›Full record

ReviewChemical science2020

Carbon-based antiviral nanomaterials: graphene, C-dots, and fullerenes. A perspective.

Plinio Innocenzi, Luigi Stagi

Abstract readReview
In one paragraph

Review in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. In Silico Analysis of CMolecules (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Fullerenol CInternational journal of nanomedicine · 2024
    Article
  19. Review
  20. Selected strategies to fight pathogenic bacteria.Journal of enzyme inhibition and medicinal chemistry · 2023
    Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Plinio InnocenziDepartment of Chemistry and Pharmacy , Laboratory of Materials Science and Nanotechnology , CR-INSTM , University of Sassari , via Vienna 2 , Sassari , 07100 , Italy . Email: plinio@uniss.it ; Email: lstagi@uniss.it.ORCID 0000-0003-2300-4680
Luigi StagiDepartment of Chemistry and Pharmacy , Laboratory of Materials Science and Nanotechnology , CR-INSTM , University of Sassari , via Vienna 2 , Sassari , 07100 , Italy . Email: plinio@uniss.it ; Email: lstagi@uniss.it.ORCID 0000-0002-7238-8425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The appearance of new and lethal viruses and their potential threat urgently requires innovative antiviral systems. In addition to the most common and proven pharmacological methods, nanomaterials can represent alternative resources to fight viruses at different stages of infection, by selective action or in a broad spectrum. A fundamental requirement is non-toxicity. However, biocompatible nanomaterials have very often little or no antiviral activity, preventing their practical use. Carbon-based nanomaterials have displayed encouraging results and can present the required mix of biocompatibility and antiviral properties. In the present review, the main candidates for future carbon nanometric antiviral systems, namely graphene, carbon dots and fullerenes, have been critically analysed. In general, different carbon nanostructures allow several strategies to be applied. Some of the materials have peculiar antiviral properties, such as singlet oxygen emission, or the capacity to interfere with virus enzymes. In other cases, nanomaterials have been used as a platform for functional molecules able to capture and inhibit viral activity. The use of carbon-based biocompatible nanomaterials as antivirals is still an almost unexplored field, while the published results show promising prospects.

Identifiers

PMID33033592
PMCPMC7499860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.